Outcome Measures: |
Primary: AUCIAsp,0h-t - Area under the serum insulin aspart concentration-time curve from 0 to t hours after investigational medicinal product (IMP) administration, where t is end of exposure, Measured in pmol\*h/L, 0 to 10 hours after IMP administration | Secondary: AUCIAsp,0-1h - Area under the serum insulin aspart concentration-time curve from 0 to 1 hour after IMP administration, Measured in pmol\*h/L, 0 to 1 hour after IMP administration|AUCIAsp,0-2h - Area under the serum insulin aspart concentration-time curve from 0 to 2 hours after IMP administration, Measured in pmol\*h/L, 0 to 2 hours after IMP administration|AUCIAsp,0-inf - Area under the serum insulin aspart concentration-time curve from 0 hours after IMP administration to infinity, Measured in pmol\*h/L, 0 to 10 hours after IMP administration|Cmax,IAsp - Maximum observed serum insulin aspart concentration, Measured in pmol/L, 0 to 10 hours after IMP administration|tmax,IAsp - Time to maximum observed serum insulin aspart concentration, Measured in minutes, 0 to 10 hours after IMP administration|Number of adverse events in the treatment emergent period, Count of events, 0 to 2 days after IMP administration|Number of local reactions at the injection site in the treatment emergent period, Count of injection site reactions, 0 to 2 days after IMP administration|Number of hypoglycaemic episodes in the treatment emergent period, Count of hypoglycaemic episodes, 0 to 16 hours after IMP administration
|